H. Burris, M. Moore, J. Andersen, M. Green, M. Rothenberg et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial., Journal of Clinical Oncology, vol.15, issue.6, pp.2403-2416, 1997.
DOI : 10.1200/JCO.1997.15.6.2403

O. Jones, J. Melling, and P. Ghaneh, Adjuvant therapy in pancreatic cancer World journal of gastroenterology: WJG, pp.14733-14779, 2014.

J. Kroep, G. Giaccone, C. Tolis, D. Voorn, W. Loves et al., Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines, British journal of cancer, vol.8320, issue.8, pp.1069-76, 2000.

R. Thota, J. Pauff, and J. Berlin, Treatment of metastatic pancreatic adenocarcinoma: a review, Oncology, vol.28, issue.1, pp.70-402, 2014.

D. Goldstein, R. El-maraghi, P. Hammel, V. Heinemann, V. Kunzmann et al., nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial, JNCI Journal of the National Cancer Institute, vol.107, issue.2, 2015.
DOI : 10.1093/jnci/dju413

D. Bouffard, J. Laliberte, and R. Momparler, Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase, Biochemical Pharmacology, vol.45, issue.9, pp.1857-61, 1993.
DOI : 10.1016/0006-2952(93)90444-2

C. Serdjebi, G. Milano, and J. Ciccolini, Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs , in press, Expert Opin Drug Metab Toxicol, 2014.

J. Ciccolini, L. Dahan, N. Andre, A. Evrard, M. Duluc et al., Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies, Journal of Clinical Oncology, vol.28, issue.1, pp.160-165, 2009.
DOI : 10.1200/JCO.2009.24.4491

A. Collins, Molecular epidemiology in cancer research Molecular aspects of medicine, pp.359-432, 1998.

J. Baker, E. Wickremsinhe, C. Li, O. Oluyedun, A. Dantzig et al., Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug metabolism and disposition: the biological fate of chemicals, pp.541-546, 2012.

D. Micozzi, F. Carpi, S. Pucciarelli, V. Polzonetti, P. Polidori et al., Human cytidine deaminase: A biochemical characterization of its naturally occurring variants, International Journal of Biological Macromolecules, vol.63, pp.64-74, 2014.
DOI : 10.1016/j.ijbiomac.2013.10.029

C. Tibaldi, E. Giovannetti, E. Vasile, V. Mey, A. Laan et al., Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research, pp.1797-803, 2008.

E. Giovannetti, A. Laan, E. Vasile, C. Tibaldi, S. Nannizzi et al., Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples, Nucleosides, Nucleotides and Nucleic Acids, vol.26, issue.6-7, pp.720-725, 2008.
DOI : 10.1126/science.286.5439.487

H. Li and X. Wang, The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: A meta-analysis. The International journal of biological markers, pp.224-256, 2014.

E. Sugiyama, N. Kaniwa, S. Kim, R. Kikura-hanajiri, R. Hasegawa et al., Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism, Journal of Clinical Oncology, vol.25, issue.1, pp.32-42, 2006.
DOI : 10.1200/JCO.2006.06.7405

M. Deenen, A. Cats, J. Beijnen, and J. Schellens, Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism, The Oncologist, vol.16, issue.6, pp.820-854, 2011.
DOI : 10.1634/theoncologist.2010-0259

C. Serdjebi, J. Seitz, J. Ciccolini, M. Duluc, E. Norguet et al., Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen, Pharmacogenomics, vol.14, issue.9, pp.1047-51, 2013.
DOI : 10.2217/pgs.13.93

J. Zhou, S. Gao, F. Zhang, B. Jiang, Q. Zhan et al., Liquid chromatography???tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma, Journal of Chromatography B, vol.906, pp.1-8, 2012.
DOI : 10.1016/j.jchromb.2012.07.033

X. Jiang, P. Galettis, M. Links, P. Mitchell, and A. Mclachlan, Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate, British Journal of Clinical Pharmacology, vol.14, issue.3, pp.326-359, 2008.
DOI : 10.1111/j.1365-2125.2003.02051.x

J. Maring, F. Wachters, M. Slijfer, J. Maurer, H. Boezen et al., Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism, European Journal of Clinical Pharmacology, vol.14, issue.4 Suppl 11
DOI : 10.1007/s00228-010-0799-0

URL : https://hal.archives-ouvertes.fr/hal-00612989

V. Ludovini, I. Floriani, L. Pistola, V. Minotti, M. Meacci et al., Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients, Journal of Thoracic Oncology, vol.6, issue.12, pp.2018-2605, 2011.
DOI : 10.1097/JTO.0b013e3182307e1f

S. Fitzgerald, R. Goyal, W. Osborne, J. Roy, J. Wilson et al., Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter, Human Genetics, vol.206, issue.Suppl 1, pp.276-83, 2006.
DOI : 10.1007/s00439-006-0142-0

E. Sugiyama, N. Kaniwa, S. Kim, R. Hasegawa, Y. Saito et al., Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients, Clinical Pharmacokinetics, vol.9, issue.3, pp.549-58, 2010.
DOI : 10.2165/11532970-000000000-00000